3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
3
Phase 2
2
Phase 3
1
Phase 1/2
1
Status
Withdrawn
1
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Cholangiocarcinoma
1
Carcinoma, Ovarian Epithelial
1
Adenocarcinoma of Lung
1
Interventions
Cyclophosphamide
142
Gemcitabine
129
Paclitaxel
125
Radiotherapy
119
Cisplatin
111
Carboplatin
111
pembrolizumab
109
Nivolumab
106
Docetaxel
90
Rituximab
86
Lenalidomide
77
Dexamethasone
76
Cytarabine
69
Bevacizumab
64
Fluorouracil
63
Etoposide
63
Oxaliplatin
62
Filgrastim
59
Peripheral Blood Stem Cell Transplantation
58
Everolimus
58
Capecitabine
58
fludarabine phosphate
57
Doxorubicin
56
Temozolomide
55
Prednisone
54
Irinotecan
53
Cetuximab
50
fludarabine
48
Ipilimumab
48
Erlotinib Hydrochloride
48
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Completed
×
bemarituzumab
×
Clear all
NCT05325866
2026-02-04
FORTITUDE-301
Amgen
Phase 1/2
Completed
260 enrolled